Loading stock…

CONMED Corporation (CNMD) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

CONMED Corporation

CNMDMarket cap $1.35BPrice $45.1

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

CONMED makes surgical devices and equipment used in operating rooms worldwide, from orthopedic tools to endoscopic systems. Surgeons in over 100 countries rely on its instruments daily, yet most patients never know its name behind their procedures.

In Bastion Portfolios?

52W Return0%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+10%7

Revenue Forecast

Rev CAGR (1y)-1%2

Rev CAGR (3y)+3%3

Rev CAGR (5y)+4%3

Earnings Forecast

EPS Growth Y+1+201%10

EPS Growth Y+2+5%5

EPS Growth Y+3+11%7

Quality

Margins

EBIT Margin11%5

Net Income Margin4%3

Free Cash Flow Margin10%6

Debt

Net Debt/EBITDA3.33

Efficiency

ROE6%3

ROA2%4

Earnings Stability55

GEAR+WEAK32

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)108

P/E Ratio (Forward 3y)89

P/BV1.38

EV Multiples

EV/EBITDA Fwd88

EV/EBIT Fwd108

Yield

Free Cash Flow Yield10.0%9

Dividend Yieldna–

Momentum

Short term

1 month return-4%5

3 month return+23%10

YTD return+11%7

Mid term

Price vs 52wHigh84%6

1 year return-1%5

Long term

3 year return-53%1

5 year return-66%1

Risk Shield

Price Risk

Beta0.76

Volatility45%4

Free Cash Flow

Free Cash Flow Margin10%6

Free Cash Flow Yield10.0%9

Quality

ROCE8%5

Earnings Stability55

Net Debt/EBITDA3.33

02Growth

Is it actually growing, and how fast?

CNMDCONMED

Revenue FY25$1.4B

GROWTH RATING↗

WEAK28 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y-1%2

Revenue, next 3Y, CAGR+3%3

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+201%10

EPS growth, FY27E+5%5

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Earnings are set to grow faster than sales (EPS about 11%/yr vs revenue 3%/yr), so margins should widen.

WATCH

Revenue grew 10%/yr over the last 3 years; forecasts see it cooling to 3%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 72% of companies worldwide.

Revenue is set to grow 3%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE38 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return+23%10

YTD return+11%7

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return-1%5

3-year return-53%1

5-year return-66%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+23%) and so far this year (+11%).

WATCH

It's down 0.7% over the past year, now 16% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over the past month (-4%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-53% over three years and -66% over five), behind 90% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on CONMED Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

CNMDCONMED

Revenue FY25$1.4B

GROWTH RATING↗

WEAK28 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y-1%2

Revenue, next 3Y, CAGR+3%3

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+201%10

EPS growth, FY27E+5%5

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Earnings are set to grow faster than sales (EPS about 11%/yr vs revenue 3%/yr), so margins should widen.

WATCH

Revenue grew 10%/yr over the last 3 years; forecasts see it cooling to 3%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 72% of companies worldwide.

Revenue is set to grow 3%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE38 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return+23%10

YTD return+11%7

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return-1%5

3-year return-53%1

5-year return-66%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+23%) and so far this year (+11%).

WATCH

It's down 0.7% over the past year, now 16% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over the past month (-4%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-53% over three years and -66% over five), behind 90% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on CONMED Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community